GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rohto Pharmaceutical Co Ltd (OTCPK:RPHCF) » Definitions » Scaled Net Operating Assets

Rohto Pharmaceutical Co (Rohto Pharmaceutical Co) Scaled Net Operating Assets : 0.53 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Rohto Pharmaceutical Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Rohto Pharmaceutical Co's operating assets for the quarter that ended in Dec. 2023 was $1,807.75 Mil. Rohto Pharmaceutical Co's operating liabilities for the quarter that ended in Dec. 2023 was $600.90 Mil. Rohto Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2023 was $2,265.60 Mil. Therefore, Rohto Pharmaceutical Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.53.


Rohto Pharmaceutical Co Scaled Net Operating Assets Historical Data

The historical data trend for Rohto Pharmaceutical Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rohto Pharmaceutical Co Scaled Net Operating Assets Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.51 0.54 0.47 0.49

Rohto Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.49 0.51 0.53 0.47

Competitive Comparison of Rohto Pharmaceutical Co's Scaled Net Operating Assets

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rohto Pharmaceutical Co's Scaled Net Operating Assets Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Scaled Net Operating Assets falls into.



Rohto Pharmaceutical Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Rohto Pharmaceutical Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2024 )
=(Operating Assets (A: Mar. 2024 )-Operating Liabilities (A: Mar. 2024 ))/Total Assets (A: Mar. 2023 )
=(1715.175-591.702)/2316.827
=0.48

where

Operating Assets(A: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2310.628 - 595.453
=1715.175

Operating Liabilities(A: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=661.747 - 34.642 - 35.403
=591.702

Rohto Pharmaceutical Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(1807.753-600.896)/2265.596
=0.53

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2376.416 - 568.663
=1807.753

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=667.794 - 36.623 - 30.275
=600.896

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rohto Pharmaceutical Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Rohto Pharmaceutical Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Rohto Pharmaceutical Co (Rohto Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-8-1, Tatsumi-nishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.

Rohto Pharmaceutical Co (Rohto Pharmaceutical Co) Headlines

From GuruFocus

Hennessy Japan Fund Semi-Annual Report April 30, 2014

By Vera Yuan Vera Yuan 06-26-2014